Cargando…
Epoetin beta for the treatment of chemotherapy-induced anemia: an update
Epoetin beta belongs to the class of erythropoiesis-stimulating agents (ESAs) that are currently available to treat anemic patients receiving chemotherapy. Chemotherapy-induced anemia affects a high percentage of cancer patients and, due to its negative effects on disease outcome and the patient’s q...
Autores principales: | Galli, Luca, Ricci, Clara, Egan, Colin Gerard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356683/ https://www.ncbi.nlm.nih.gov/pubmed/25784818 http://dx.doi.org/10.2147/OTT.S77497 |
Ejemplares similares
-
Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
por: Macpherson, Iain RJ, et al.
Publicado: (2009) -
Recombinant human epoetin beta in the treatment of renal anemia
por: Locatelli, Francesco, et al.
Publicado: (2007) -
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018) -
Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2016) -
Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease
por: Ohashi, Naro, et al.
Publicado: (2012)